Personalized Medicine in Woman Lung Cancer: Crizotinib and Osimertinib Association to Overcome Osimertinib Resistance

Author(s): Fanny Leenhardt, Marie Viala, Stephane Pouderoux, Pierre Boisselier, Xavier Quantin

Non-small cell lung cancer (NSCLC) is the second most diagnosed cancer in women. Research on this type of cancer has benefited from the development of precision medicine for several years. In this case study, elderly women was treated for an advanced NSCLC with brain localization and who has been treated by novel association, osimertinib and crizotinib, in front of dual mutation (EGFR and CMet). This combination of targeted therapies succeeded to partial response on primary lung tumor and total reduction on brain metastasis.